Literature DB >> 3190733

Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro.

A Tunek1, E Levin, L A Svensson.   

Abstract

Tritiated bambuterol, a bis-dimethylcarbamate prodrug of terbutaline, was incubated in vitro with blood from both sexes of the following species: man, guinea pig, rat, mouse, dog and rabbit. The rates of hydrolysis of bambuterol to its monocarbamate derivative and further to terbutaline were measured. Large species variations were observed, e.g. blood from two of the human subjects was 15-fold more active than blood from the male rats. The rate of terbutaline formation as a function of initial bambuterol concentration was investigated in human plasma, and was found to describe a bell-shaped curve. Several pieces of evidence indicated that butyrylcholinesterase (EC 3.1.1.8) is the blood enzyme predominantly responsible for hydrolysis of bambuterol, although minor contributions from other esterases cannot be excluded. An exception may be blood from the rabbit, where the kinetics of the hydrolysis was different than in blood from the other species. The kinetics of bambuterol hydrolysis is discussed on basis of the established mechanism of carbamate interactions with cholinesterases, and the high affinity of bambuterol for butyrylcholinesterase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190733     DOI: 10.1016/0006-2952(88)90068-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 2.  Clinical pharmacokinetics of bambuterol.

Authors:  D S Sitar
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

3.  Pharmacokinetics of bambuterol during oral administration to asthmatic children.

Authors:  H Ahlström; J Alvero; R Alvero; R Espos; L Fajutrao; J Herrera; B Kjellman; J Kubista; C Leviste; P Meyer; G Oldaeus; A Siricururat; P Vichyanond; G Wettrell; E Wong; L Laxmyr; L Nyberg; H Olsson; E Weibull; J Rosenborg
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

4.  Partial purification and characterization of soluble isoform of butyrylcholinesterase from rat intestine.

Authors:  Ozlem Yildiz; Ebru Bodur; A Neşe Cokuğraş; Nazmi Ozer
Journal:  Protein J       Date:  2004-02       Impact factor: 2.371

5.  Bambuterol and terbutaline in human cerebrospinal fluid and plasma.

Authors:  B Rosberg; C Schröder; L Nyberg; J Rosenborg; J E Wirén
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults.

Authors:  J Rosenborg; P Larsson; L Nyberg
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

7.  Pharmacokinetics of bambuterol in healthy subjects.

Authors:  L Nyberg; J Rosenborg; E Weibull; S Jönsson; B M Kennedy; M Nilsson
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

10.  Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase.

Authors:  I Manoharan; A Kuznetsova; J D Fisk; R Boopathy; O Lockridge; S Darvesh
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.